AAM, Perrigo Urge FDA to Clarify ANDA Submission Guidance

Drug Industry Daily
A A
The FDA should revise its draft guidance on ANDA submissions to clarify sponsors’ responsibility for reviewing existing guidances on generics, stakeholders said in comments to the agency.

To View This Article:

Login

Subscribe To Drug Industry Daily